摘要
目的分析Ki-67增殖指数、MGMT启动子甲基化及TERT启动子突变评估IDH突变型原发性胶质母细胞瘤患者预后的价值。方法对13例IDH突变型原发性胶质母细胞瘤样本分别通过免疫组化检测Ki-67增殖指数、焦磷酸测序检测MGMT启动子甲基化状态和巢式PCR和Sanger测序检测TERT启动子突变状态。结果 Ki-67增殖指数>50%和MGMT启动子低甲基化是IDH突变型原发性胶质母细胞瘤患者预后不良的指标(P<0.05),而TERT启动子突变率在IDH突变型原发性胶质母细胞瘤中较低(2/13),预后评估效果相对较弱(P>0.05)。结论 Ki-67增殖指数和MGMT启动子甲基化可以作为IDH突变型原发性胶质母细胞瘤患者临床预后评估的有效指标。
Objective To analyze the value of Ki-67 proliferation index,MGMT promoter methylation and TERT promoter mutation in evaluating the prognosis of the patients with IDH mutation type primary glioblastoma.Methods Ki-67 proliferation index was detected by immunohistochemistry,MGMT promoter methylation was detected by pyrosequencing,and TERT promoter mutation was detected by nested PCR and Sanger sequencing.Results Ki-67 proliferation index( >50%)and MGMT promoter methylation were the significant indicators of poor prognosis in the patients with IDH mutation(P<0.05),while the mutation rate of TERT promoter was lower in IDH-mutated primary glioblastoma(2/13)with a relative weak efficiency of predicting the prognosis of the patients with IDH mutation type primary glioblastoma(P >0.05).Conclusion Ki-67 proliferation index and MGMT promoter methylation can be used as the effective indicators for evaluating the prognosis of the patients with IDH mutation type primary glioblastoma.
作者
孙毅
王协锋
颜伟
SUN Yi;WANG Xiefeng;YAN Wei(Department of Neurosurgery,First Affiliated Hospital,Nanjing Medical University,Nanjing 210029,CHINA)
出处
《江苏医药》
CAS
2018年第12期1422-1424,共3页
Jiangsu Medical Journal